Breast cancer risk assessment: a non-invasive multiparametric approach to stratify patients by MMP-9 serum activity and RhoA expression patterns in circulating leucocytes

Amino Acids

Volumn 49, Issue 2, 2017, Pages 273-281

  Golubnitschaja, Olga ^a,b   Yeghiazaryan, Kristina ^a,b   Abraham, Jella Andrea ^a,b   Schild, Hans H ^a   Costigliola, Vincenzo ^b   Debald, Manuel ^a   Kuhn, Walther ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b European Association for Predictive   (Belgium)

Author keywords

Benignant breast alteration; Biomarker pattern; Blood test; Breast cancer; Metalloproteinase 9; Metastatic disease; Molecular targets; Patient stratification; Predictive medicine; Rho GTPase

Indexed keywords

GELATINASE B; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, HUMAN; TUMOR MARKER;

ANALYSIS OF VARIANCE; ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVITY; EPITOPE MAPPING; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MICROCIRCULATION; MOLECULAR DYNAMICS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; ADULT; BLOOD; BREAST DISEASE; BREAST TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; POSTMENOPAUSE; PREMENOPAUSE; PROCEDURES;

ADULT; BIOMARKERS, TUMOR; BREAST DISEASES; BREAST NEOPLASMS; FEMALE; HUMANS; LEUKOCYTES; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RHOA GTP-BINDING PROTEIN; RISK ASSESSMENT;

EID: 84994257515     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-016-2357-2     Document Type: Article

References (43)

1. Abraham J-A, Golubnitschaja O (2016) Time for paradigm change in management of hepatocellular carcinoma: is an personalized approach on the horizon? Pers Med 13:455–467. doi:10.2217/pme-2016-0013
2. Bhandary L, Whipple RA, Vitolo MI et al (2015) ROCK inhibition promotes microtentacles that enhance reattachment of breast cancer cells. Oncotarget 6:6251–6266. doi:10.18632/oncotarget.3360
3. Braun M, Fountoulakis M, Papadopoulou A et al (2009) Down-regulation of microfilamental network-associated proteins in leukocytes of breast cancer patients: potential application to predictive diagnosis. Cancer Genom Proteom 6:31–40
4. Cáceres M, Guerrero J, Martínez J (2005) Overexpression of RhoA-GTP induces activation of the epidermal growth factor receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells. Exp Cell Res 309:229–238. doi:10.1016/j.yexcr.2005.05.020
5. Camara O, Kavallaris A, Nöschel H et al (2006) Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World J Surg Oncol 4:67. doi:10.1186/1477-7819-4-67
6. Carr HS, Zuo Y, Oh W, Frost JA (2013) Regulation of focal adhesion kinase activation, breast cancer cell motility, and amoeboid invasion by the RhoA guanine nucleotide exchange factor Net1. Mol Cell Biol 33:2773–2786. doi:10.1128/MCB.00175-13
7. Chang Y-WE, Marlin JW, Chance TW, Jakobi R (2006) RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility. Cancer Res 66:11700–11708. doi:10.1158/0008-5472.CAN-06-1818
8. Cheng H, Wang L, Mollica M et al (2014) Nitric oxide in cancer metastasis. Cancer Lett 353:1–7. doi:10.1016/j.canlet.2014.07.014
9. Covington KR, Brusco L, Barone I et al (2013) Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Res Treat 141:375–384. doi:10.1007/s10549-013-2709-5
10. Cox TR, Rumney RMH, Schoof EM et al (2015) The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522:106–110. doi:10.1038/nature14492
11. Debald M, Yeghiazaryan K, Cebioglu M et al (2013) “Suspect molecular signature” in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention. EPMA J 4:22. doi:10.1186/1878-5085-4-22
12. Duffy MJ, McGowan PM, Harbeck N et al (2014) uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 16:428. doi:10.1186/s13058-014-0428-4
13. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174. doi:10.1038/nrc745
14. Fagan-Solis KD, Schneider SS, Pentecost BT et al (2013) The RhoA pathway mediates MMP-2 and MMP-9-independent invasive behavior in a triple-negative breast cancer cell line. J Cell Biochem 114:1385–1394. doi:10.1002/jcb.24480
15. Friedl P, Wolf K (2010) Plasticity of cell migration: a multiscale tuning model. J Cell Biol 188:11–19. doi:10.1083/jcb.200909003
16. Fritz G, Just I, Kaina B (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682–687
17. Girotra S, Yeghiazaryan K, Golubnitschaja O (2016) Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics. Pers Med 13:469–484. doi:10.2217/pme-2016-0020
18. Goldfarb Y, Ben-Eliyahu S (2006) Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches. Breast Dis 26:99–114
19. Golubnitschaja O, Sridhar KC (2016) Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes. Clin Exp Metastasis. doi:10.1007/s10585-016-9816-8
20. Golubnitschaja O, Yeghiazaryan K, Costigliola V et al (2013) Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J 4:6. doi:10.1186/1878-5085-4-6
21. Golubnitschaja O, Debald M, Kuhn W et al (2016a) Flammer syndrome and potential formation of pre-metastatic niches: a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease. EPMA J 7(Suppl 1):A25. doi:10.1186/s13167-016-0054-6
22. Golubnitschaja O, Debald M, Yeghiazaryan K et al (2016b) Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumour Biol. doi:10.1007/s13277-016-5168-x
23. Golubnitschaja O, Yeghiazaryan K, Stricker H et al (2016c) Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours. BMC Cancer 16:357. doi:10.1186/s12885-016-2382-2
24. Golubnitschaja-Labudova O, Liu R, Decker C et al (2000) Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr Eye Res 21:867–876
25. Gou L, Wang W, Tong A et al (2011) Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma. J Mol Med 89:817–827. doi:10.1007/s00109-011-0753-3
26. Harms W, Malter W, Krämer S et al (2014) Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer. Anticancer Res 34:4457–4462
27. Jacobs VR, Kates RE, Kantelhardt E et al (2013) Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer. Breast Cancer Res Treat 138:839–850. doi:10.1007/s10549-013-2496-z
28. Konieczka K, Ritch R, Traverso CE et al (2014) Flammer syndrome. EPMA J 5:11. doi:10.1186/1878-5085-5-11
29. Leppä S, Saarto T, Vehmanen L et al (2004) A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 10:1057–1063
30. Marino N, Woditschka S, Reed LT et al (2013) Breast cancer metastasis: issues for the personalization of its prevention and treatment. Am J Pathol 183:1084–1095. doi:10.1016/j.ajpath.2013.06.012
31. Mehner C, Hockla A, Miller E et al (2014) Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget 5:2736–2749. doi:10.18632/oncotarget.1932
32. Muñoz-Nájar UM, Neurath KM, Vumbaca F, Claffey KP (2006) Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 25:2379–2392. doi:10.1038/sj.onc.1209273
33. Narumiya S, Tanji M, Ishizaki T (2009) Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 28:65–76. doi:10.1007/s10555-008-9170-7
34. Provatopoulou X, Gounaris A, Kalogera E et al (2009) Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 9:390. doi:10.1186/1471-2407-9-390
35. Ranuncolo SM, Armanasco E, Cresta C et al (2003) Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106:745–751. doi:10.1002/ijc.11288
36. Raviraj V, Fok S, Zhao J et al (2012) Regulation of ROCK1 via Notch1 during breast cancer cell migration into dense matrices. BMC Cell Biol 13:12. doi:10.1186/1471-2121-13-12
37. Sanz-Moreno V, Marshall CJ (2010) The plasticity of cytoskeletal dynamics underlying neoplastic cell migration. Curr Opin Cell Biol 22:690–696. doi:10.1016/j.ceb.2010.08.020
38. Sayagués JM, Corchete LA, Gutiérrez ML et al (2016) Genomic characterization of liver metastases from colorectal cancer patients. Oncotarget. doi:10.18632/oncotarget.12140
39. Sun K, Duan X, Cai H et al (2016) Curcumin inhibits LPA-induced invasion by attenuating RhoA/ROCK/MMPs pathway in MCF7 breast cancer cells. Clin Exp Med 16:37–47. doi:10.1007/s10238-015-0336-7
40. Sung H, Choi J-Y, Lee S-A et al (2012) The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer. BMC Cancer 12:193. doi:10.1186/1471-2407-12-193
41. Tabariès S, Ouellet V, Hsu BE et al (2015) Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast Cancer Res 17:45. doi:10.1186/s13058-015-0558-3
42. Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89:1270–1275. doi:10.1038/sj.bjc.6601238
43. WHO (2012) WHO|cancer. In: WHO. http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed 15 Jun 2016